The causal relation between human papillomavirus and cervical cancer.

By F. Bosch, A. Lorincz, N. Muñoz, C. J. Meijer, K. Shah. Journal of Clinical Pathology, 2002

3,669 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer. (2012, background): “The recognition of the strong causal relationship between peristent cervical infection with high-risk human papillomavirus HPV) types and occurrence of cervical cancer [1] has led to the evelopment of a series of HPV DNA or RNA tests.”
Cancer of the cervix uteri (2018, methodology): “52,66,67 In areas where radiotherapy facilities are scarce, neoadjuvant chemotherapy (NACT) has been used with the goal of: (1) down- staging of the tumor to improve the radical curability and safety of surgery; and (2) inhibition of micrometastasis and distant metastasis.”
The papillomavirus life cycle. (2005, background): “By contrast, the high-risk viruses from supergroup A, such as HPV16 and 18, cause mucosal lesions that can progress in some individuals to high-grade neoplasia and cancer (Bosch et al., 2002; Walboomers et al., 1999).”
Roles of the immune system in cancer: from tumor initiation to metastatic progression (2018, background): “For example, human papilloma viruses (HPVs) induce inflammation and are responsible for 90% – 100% of all cervical cancers (Bosch et al. 2002).”